Debra J. Palmer

Nov 1, 2024 | sciencedirect.com | Nikolaos Lazaridis |Edward J Despott |Debra J. Palmer |Y. Ho Shin

Section snippetsReal-world data studiesIn children 6 to 11 years of age, the efficacy and safety of omalizumab as add-on therapy supported by randomized controlled trial (RCT) evidence have been confirmed in real-world studies (RWS) (Table I).

Sep 2, 2024 | sciencedirect.com | Pedro A Lamothe |F. Eun-Hyung Lee |Debra J. Palmer |Susan L. Prescott

Supported by the (grant K23 AI163371 [to L.L.]. Disclosure of potential conflict of interest: K. G. Blumenthal receives grant support from the Agency for Healthcare Research and Quality (grant R01 HS029319) and the National Institutes of Health (grant U01 AI184071), prior grant support from Phadia Ab (Thermo Fisher Scientific), and royalties from UpToDate, outside of the submitted work. The remaining author declares that she has no relevant conflicts of interest.